MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Income Overview
Net Income
-$1,243,554
EPS
-$0.75
Unit: Dollar
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Income Statement
2025-09-30
2025-06-30
Research and development expenses
6,673
10,631
General and administrative expenses
928,114
628,233
Total operating expenses
934,787
638,864
Loss from operations
-934,787
-638,864
Interest income (expense), net
-36,069
-36,067
Total other expenses
-36,069
-36,067
Loss from continued operations
-970,856
-674,931
Net loss from continued operations
-970,856
-674,931
Loss from discontinued operations net of tax
-181,953
-323,340
Net loss
-1,152,809
-998,271
Preferred stock dividends
90,745
82,165
Net loss applicable to common shareholders
-1,243,554
-1,080,436
Basic EPS
-0.75
-0.21
Diluted EPS
-0.75
-0.21
Basic Average Shares
1,652,679
4,765,004
Diluted Average Shares
1,652,679
4,765,004
Page 1
Unit: Dollar. Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Income Statement
Net loss applicable
to common...
-$1,243,554
Net loss
-$1,152,809
Preferred stock dividends
$90,745
Net loss from
continued operations
-$970,856
Loss from
discontinued operations net...
-$181,953
Loss from continued
operations
-$970,856
Loss from operations
-$934,787
Total other expenses
-$36,069
Total operating
expenses
$934,787
Interest income
(expense), net
-$36,069
General and
administrative expenses
$928,114
Research and development
expenses
$6,673
Buy us a coffee
Entero Therapeutics, Inc. (ENTO)
Entero Therapeutics, Inc. (ENTO)